Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76(2):265–81. https://doi.org/10.1053/j.ajkd.2019.10.017.
Article
PubMed
Google Scholar
Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006;15(5):308–18. https://doi.org/10.1191/0961203306lu2305xx.
Article
CAS
PubMed
Google Scholar
Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–96. https://doi.org/10.1016/j.kint.2017.11.023.
Article
PubMed
Google Scholar
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808. https://doi.org/10.1002/acr.21664.
Article
Google Scholar
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713 LP – 723. https://doi.org/10.1136/annrheumdis-2020-216924.
Article
CAS
Google Scholar
Cattran DC, Feehally J, Cook HT, et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. https://doi.org/10.1038/kisup.2012.9.
Article
Google Scholar
Disease R, Rheum A, Rheumatology C. KDIGO GN Guideline update – Evidence summary Lupus nephritis Antimalarial therapy for lupus nephritis. Published online 2018:1–7.
Mok CC, Yap DYH, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis. 2013;16(6):625–36. https://doi.org/10.1111/1756-185X.12212.
Article
CAS
PubMed
Google Scholar
Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. Published online 1986. https://doi.org/10.1056/NEJM198603063141004
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. Published online 2009. https://doi.org/10.1681/ASN.2008101028
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–31. https://doi.org/10.1002/art.10461.
Article
CAS
PubMed
Google Scholar
Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian Aborigines: high prevalence, morbidity and mortality. Aust N Z J Med. 1993;23(6):646–51. https://doi.org/10.1111/j.1445-5994.1993.tb04720.x.
Article
CAS
PubMed
Google Scholar
Segasothy M, Phillips PA. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: A comparative study. Lupus. 2001;10(6):439–44. https://doi.org/10.1191/096120301678646191.
Article
CAS
PubMed
Google Scholar
Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus. 2003;12(4):327–31. https://doi.org/10.1191/0961203303lu381xx.
Article
CAS
PubMed
Google Scholar
Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian Aboriginals. Aust N Z J Med. 1995;25(2):182–3. https://doi.org/10.1111/j.1445-5994.1995.tb02843.x.
Article
CAS
PubMed
Google Scholar
Vincent FB, Bourke P, Morand EF, Mackay F, Bossingham D. Focus on systemic lupus erythematosus in Indigenous Australians: Towards a better understanding of autoimmune diseases. Intern Med J. 2013;43(3):227–34. https://doi.org/10.1111/imj.12039.
Article
CAS
PubMed
Google Scholar
Mason JA, Bossingham D. The clinical characterisation of systemic lupus erythematosus in a Far North Queensland Indigenous kindred. Lupus. 2009;18(2):144–8. https://doi.org/10.1177/0961203308094997.
Article
CAS
PubMed
Google Scholar
Department of Health NG. 2019–2020 Department of Health Annual Report. Published online 2020.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.
Article
PubMed
PubMed Central
Google Scholar
Nigam A, Baer R, Green S, Neuen BL, Vile A, Mantha M. Lupus nephritis in Indigenous Australians: a single-centre study. Intern Med J. 2020;50(7):830–7. https://doi.org/10.1111/imj.14710.
Article
CAS
PubMed
Google Scholar
Ghazanfari F, Jabbar Z, Nossent J. Renal histology in Indigenous Australians with lupus nephritis. Int J Rheum Dis. 2018;21(1):194–9. https://doi.org/10.1111/1756-185X.13147.
Article
PubMed
Google Scholar
Australian Institute of Health and Welfare. Aboriginal-and-Torres-Strait-Islander-Health-Performance-Framework-2017-report-Northern-Territory. Published online 2017.
Majoni SW, Hughes JT, Heron B, Currie BJ. Trimethoprim+Sulfamethoxazole Reduces Rates of Melioidosis in High-Risk Hemodialysis Patients. Kidney Int Rep. 2017;3(1):160–7. https://doi.org/10.1016/j.ekir.2017.09.005.
Article
PubMed
PubMed Central
Google Scholar
Boan P, Swaminathan R, Irish A. Infectious complications in indigenous renal transplant recipients in Western Australia. Int Med J Published online. 2017. https://doi.org/10.1111/imj.13450.
Article
Google Scholar
Ghazanfari F, Jabbar Z, Nossent J. Renal histology in Indigenous Australians with lupus nephritis. Int J Rheum Dis. 2018;21(1):194–9. https://doi.org/10.1111/1756-185X.13147.
Article
PubMed
Google Scholar
Chan TM, Tse KC, Tang CSO, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076–84. https://doi.org/10.1681/ASN.2004080686.
Article
CAS
PubMed
Google Scholar
Ginzler EM, Anne Dooley M, Aranow C, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. n engl j med. 2005;353. www.nejm.org. Accessed 30 Apr 2022.
Meder KN, Jayasinghe S, Beard F, et al. Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalizations in indigenous and non-indigenous Australians. Clin Infect Dis. 2020;70(12):2607–15. https://doi.org/10.1093/cid/ciz731.
Article
CAS
PubMed
Google Scholar
May PJ, Bowen AC, Carapetis JR. The inequitable burden of group a streptococcal diseases in indigenous Australians: We need to fill evidence gaps and make clinical advances to reduce these diseases of disadvantage. Med J Aust. 2016;205(5):201–4. https://doi.org/10.5694/mja16.00400.
Article
PubMed
Google Scholar
Johnston FH, Morris PS, Speare R, et al. Strongyloidiasis: A review of the evidence for Australian practitioners. Aust J Rural Health. 2005;13(4):247–54. https://doi.org/10.1111/j.1440-1584.2005.00710.x.
Article
PubMed
Google Scholar
Bright A, Denholm J, Coulter C, Waring J, Stapledon R. Tuberculosis notifications in Australia, 2015–2018. Commun Dis Intell. 2018;2020(44):2015–8. https://doi.org/10.33321/cdi.2020.44.88.
Article
Google Scholar
Ioannides S, Beard F, Larter N, et al. Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015. Commun Dis Intell. 2018;2019(43):2011–5. https://doi.org/10.33321/cdi.2019.43.36.
Article
Google Scholar
Acute-rheumatic-fever-and-rheumatic-heart-disease-in-Australia-2015–2019.
Meumann EM, Horan K, Ralph AP, et al. Tuberculosis in Australia’s tropical north: a population-based genomic epidemiological study. The Lancet Regional Health – Western Pacific. 2021;15. https://doi.org/10.1016/j.lanwpc.2021.100229
Davis JS, Cheng AC, McMillan M, Humphrey AB, Stephens DP, Anstey NM. Sepsis in the tropical Top End of Australia’s Northern Territory: disease burden and impact on Indigenous Australians. Med J Aust. 2011;194(10):519–24. https://doi.org/10.5694/J.1326-5377.2011.TB03088.X.
Article
PubMed
Google Scholar
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–26. https://doi.org/10.1002/art.34359.
Article
CAS
PubMed
Google Scholar
Wongseelashote S, Tayal V, Bourke PF. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008–2016. Intern Med J. 2018;48(2):165–72. https://doi.org/10.1111/imj.13554.
Article
PubMed
Google Scholar
Tong SYC, McDonald MI, Holt DC, Currie BJ. Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations. Clinical Infect Dis. 2008;46(12):1871–8. https://doi.org/10.1086/588301.
Article
Google Scholar
Bailie RS, Stevens MR, McDonald E, et al. Skin infection, housing and social circumstances in children living in remote Indigenous communities: testing conceptual and methodological approaches. BMC Public Health. 2005;5:128. https://doi.org/10.1186/1471-2458-5-128.
Article
PubMed
PubMed Central
Google Scholar
Davidson L, Knight J, Bowen AC. Skin infections in Australian Aboriginal children: a narrative review. Med J Aust. 2020;212(5):231–7. https://doi.org/10.5694/mja2.50361.
Article
PubMed
Google Scholar
Colosia AD, Masaquel A, Hall CB, Barrett AM, Mahadevia PJ, Yogev R. Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review. BMC Infect Dis. 2012;12:95. https://doi.org/10.1186/1471-2334-12-95.
Article
PubMed
PubMed Central
Google Scholar